NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition

Plain-language summary

Published 2025 in bioRxiv, this work by Kim A and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Mechanistic study in bioRxiv (2025) on NAD+/sirtuin/longevity biology
• Adds to the foundational literature underlying NMN supplementation rationale
• First author: Kim A

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.